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1897-908.
Conclusion: Polymorphisms of the C-reactive protein (CRP) gene are
associated with increases in CRP levels but are not in themselves associated
with an increased risk of ischemic vascular disease.
Summary: It is well known that elevated plasma levels of CRP are
associated with an increased risk of ischemic cerebrovascular and ischemic
cardiac disease. What is unknown is whether CRP levels themselves contrib-
ute to causation of ischemic cerebrovascular or cardiac disease, or are merely
markers of the existence of ischemic cerebrovascular or cardiovascular dis-
ease. The CRP gene has genetic variations that increase levels of CRP to
different degrees and therefore can theoretically be used to assess the
consequences of lifelong high CRP levels independent of additional risk
factors. The authors of this study sought to determine whether genetically
elevated CRP levels caused an increased risk of ischemic heart disease and
ischemic cerebrovascular disease.
The study included 10,276 people from a general population cohort.
Ischemic heart disease developed in 1786, and ischemic cerebrovascular
disease developed in 741. In an additional cohort of 31,992 persons from
the general population, 2521 had ischemic heart disease and 1483 had
ischemic cerebrovascular disease. The authors also studied an additional
2238 patients with ischemic heart disease and 4474 control participants
along with 612 patients with ischemic cerebrovascular disease and an addi-
tional 1224 control participants. High-sensitivity CRP was measured, fol-
lowed with genotyping of four CRP polymorphisms and two apolipoprotein
E polymorphisms.
In persons with CRP levels3 mg/L, compared with those with CRP
levels 1 mg/L, ischemic heart disease was increased by a factor of 1.6 and
ischemic cerebrovascular disease was increased by a factor of 1.3. The four
CRP polymorphisms resulted in an increase in CRP levels of up to 64%.
Theoretically, this would predict an increased risk of 32% for ischemic heart
disease and 25% for ischemic cerebrovascular disease. However, no genotype
combination was associated with an increased risk of either ischemic cere-
brovascular or ischemic cardiac disease. Apolipoprotein E genotypes were
associated with an increased risk of ischemic heart disease and elevated
cholesterol levels.
Comment: Drugs are being developed to specifically target lowering
CRP levels (Curr Atheroscler Rep 2006;8:421-8). The ultimate goal would
be to lower CRP levels and, if CRP is associated with causing atherosclerosis,
ultimately prevent the development of vascular disease. This study suggests
that such a strategy is likely to be “barking up the wrong tree.” Although
epidemiologic studies have observed an increased risk of ischemic vascular
disease associated with higher plasma CRP levels, the current data indicate
that increased CRP levels are perhaps more a marker for atherosclerosis than
a cause of atherosclerosis. Please see also the abstract for a related article
(N Engl J Med 2008;359:2195-207).
Rosuvastatin to Prevent Vascular Events in Men and Women with
Elevated C-Reactive Protein
Ridker, PM, Danielson E, Fonseca FAH, and the JUPITER Study Group. N
Engl J Med 2008;359:2195-207.
Conclusions: In patients with elevated high-sensitivity C-reactive pro-
tein (CRP) levels, who are otherwise apparently healthy without hyperlipid-
emia, rosuvastatin significantly reduced major cardiovascular events.
Summary: Increased levels of CRP, an inflammatory biomarker, pre-
dict cardiovascular events. Statin medications have been known to lower
cholesterol and levels of high-sensitivity CRP. The authors hypothesized
that patients with elevated high-sensitivity CRP levels, but with normal lipid
levels, might benefit from statin treatment. This was a randomized prospec-
tive clinical trial comprising 17,802 apparently healthy women andmenwith
low-density lipoprotein cholesterol (LDL-C) levels 130 mg/dL and with
high-sensitivity CRP levels 2.0 mg/dL. Patients were randomly assigned
to rosuvastatin (20 mg daily) or placebo. They were then monitored for the
occurrence of the primary end point of myocardial infarction, arterial revas-
cularization, hospitalization for unstable angina, stroke, or death from
cardiovascular causes.
After a median of 1.9 years of follow-up, the trial was stopped by the
safety monitoring committee. LDL-C levels were reduced by rosuvastatin by
50% and high-sensitivity C-reactive protein levels were reduced by 37%. The
rates of the primary end point were 0.77 and 1.36 per 100 patient-years of
follow-up in the rosuvastatin and placebo groups, respectively. Rosuvastatin
had a hazard ratio (HR) of 0.56 (95% confidence interval [CI], 0.46-0.69;
P  .00001). Rates for myocardial infarction were 0.17 and 0.37 per 100
534person-years in the rosuvastatin and placebo groups, respectively (HR, 0.46;
95% CI 0.30-0.70; P  .0002). For stroke, corresponding rates for 100
person-years were 0.18 and 0.34 for rosuvastatin and placebo groups (HR,
0.52; 95% CI 0.34-0.79; P  .002). Rates per 100 patient-years for
revascularization or unstable angina were 0.41 and 0.77 for the rosuvastatin
and placebo groups, respectively (HR, 0.53; 95% CI, 0.40-0.7; P 
.00001). For a combined end point of myocardial infarction, stroke, or
death from cardiovascular causes, the rates for rosuvastatin and placebo per
100 patient-years were 0.45 and 0.85, respectively (HR, 0.53; 95% CI
0.4-0.69; P  .00001). Finally, for death from any cause, rates for rosuvas-
tatin and placebo were 1.00 and 1.25 per 100 patient-years, respectively
(HR, 0.80; 95% CI, 0.67-0.97; P  .02). No significant increase in myop-
athy or cancer was noted in the rosuvastatin patients, but they did have a
higher incidence of diabetes.
Comment: The findings of this study are compatible with the now
well-accepted postulate that inflammation contributes to and is essential to
the atherosclerotic process. This study was stopped relatively soon after its
inception, and this raises the possibility that the events that occurred may be
independent of the usual mechanisms of progression of atherosclerotic
plaque. It does seem unusual that patients who have LDL-C levels that are
generally regarded as favorable would have marked progression of athero-
sclerosis in such a short time. The results may therefore indicate more of a
plaque stabilization effect of lowering CRP levels than inhibition of bulky
progression of existing plaque. The article should be examined in the context
of another article, also from the New England Journal of Medicine (N Engl
J Med 2008;359:1897-908), that is also abstracted in this issue of the
Journal of Vascular Surgery. This second article suggests that treatment of
CRP alone would be unlikely to be of benefit in patients at risk for
cardiovascular events. However, the two articles are not necessarily incom-
patible. It is reasonable to postulate that to derive benefit from treatment of
elevated CRP, it is also necessary to drive down the LDL-C level. Trials will
eventually be required with agents that can lower CRP—but not affect
cholesterol levels—to tease out the mechanism of benefit of rosuvastatin
therapy in patients with otherwise “acceptable” LDL-C levels and eleva-
ted CRP.
Anatomic Suitability of Ruptured Abdominal Aortic Aneurysms for
Endovascular Repair
Slater BJ, Harris EJ, Lee JT. Ann Vasc Surg 2008;22:716-22.
Conclusions: Only about half of patients with ruptured abdominal
aortic aneurysms (rAAAs) are candidates for endovascular aneurysm repair
(EVAR) with conventional stent graft devices.
Summary: Open surgical repair is the traditional strategy to treat
patients with rAAAs. The mortality rate is approximately 50%. There is now
considerable enthusiasm for EVAR of rAAAs. Small case series suggest
EVAR is feasible for rAAAs and may be associated with improved short-term
morbidity and mortality compared with open repair. Only one randomized
controlled study has compared open vs endovascular repair of rAAAs,
however, and it showed no difference in outcome (Eur J Vasc Endovasc Surg
2006;32:506-14).
The authors sought to investigate anatomic suitability of rAAAs for
EVAR by review of preoperative cross-sectional imaging. They retrospec-
tively analyzed a consecutive series of rAAAs. Imaging studies were used to
determine if EVAR could have been feasible based on available devices at the
time of data collection for the study. If the patients had an aortic neck
diameter 32 mm, a neck length 10 mm, neck angulation 60° severe
iliac tortuosity, or external iliac artery diameters6 mm, they were declared
noncandidates for EVAR.
During a 10-year period, 47 rAAAs were treated at this institution, of
which 60% were transferred from referring hospitals and 47% had free
rupture. During the past 2 years, five (11%) had been treated with EVAR,
and the remaining 42 patients underwent open repair. Preoperative imaging
was available in 43 of the 47 patients treated. Morphologic measurements
based on the criteria noted above indicated 49% would have been candidates
for EVAR. EVAR was precluded by inadequate neck length in 73%, unsuit-
able iliac access in 23%, large neck diameter in 18%, and severe angulation of
the aneurysm neck in 14%. The 30-day operative mortality rate was 34%, and
1-year mortality was 42%. EVAR candidates were more likely to be men
(95% vs 68%, P  .046), to have smaller sac diameters (7.0 vs 8.5 cm, P 
.0.2), and longer length necks (24.1 vs 8.6 mm, P .0001). They were also
less likely to have 60° angulated neck (10% vs 45%, P  .0002) and more
likely to have larger external iliac artery diameters (8.9 vs 7.3mm, P .015).
Comment: The results of this study, using a retrospective analysis of
cases up to 10 years ago, would seem to be relatively applicable to the
anatomy of patients currently with rAAAs. Anatomy of rAAAs is unlikely to
